Levetiracetam Sciecure

Levetiracetam, the active ingredient in Levetiracetam Sciecure, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients who require parenteral therapy.

GNH USA supplies Levetiracetam Sciecure as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is used in the management of epilepsy, targeting neuronal hyperexcitability.

Partial‑onset seizures: reduces the frequency of focal seizure episodes. Generalized tonic‑clonic seizures: helps control convulsive episodes in generalized epilepsy. Myoclonic seizures: decreases the occurrence of rapid muscle jerks in appropriate seizure types.

Levetiracetam may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias such as neutropenia or thrombocytopenia - Suicidal thoughts or severe depression - Hepatic failure (very rare)

When using Levetiracetam Sciecure, consider the following safety measures.

Renal impairment: adjust dose based on creatinine clearance. Behavioral changes: monitor patients for agitation, aggression or mood swings. Hypersensitivity: discontinue if a rash or other allergic signs develop. Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited. Severe skin reaction: stop treatment immediately if signs of Stevens‑Johnson syndrome appear. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levetiracetam can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Co‑administration with strong enzyme inducers such as phenobarbital, phenytoin or carbamazepine may reduce levetiracetam plasma concentrations.

Moderate Interactions (Monitor Closely): - Concurrent use with other central nervous system depressants (e.g., benzodiazepines) may increase sedation. - Combined with oral contraceptives, levetiracetam may lower contraceptive efficacy; additional barrier methods are advised. - Use with nephrotoxic agents may heighten the risk of renal impairment; monitor renal function regularly.